# Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

> **NCT01598168** · PHASE3 · TERMINATED · sponsor: **McMaster University** · enrollment: 22 (actual)

## Conditions studied

- Heparin-induced Thrombocytopenia

## Interventions

- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT01598168
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01598168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01598168, "Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01598168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*